SCHEMBL3021973

SCHEMBL3021973

O=S(=O)(c1ccc(Cl)c(Cl)c1)N1CCN(c2nc(Cc3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD11B1 P28845 3/20 0.43
RAB9A P51151 1/20 0.43
LPAR1 Q92633 4/20 0.42
LPAR2 Q9HBW0 4/20 0.42
MAPK1 P28482 1/20 0.41
AR P10275 1/20 0.41
ADRB3 P13945 1/20 0.41
TSPO P30536 1/20 0.41
DRD3 P35462 1/20 0.41
OPRK1 P41145 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
LPAR4 Q99677 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
GPR35 Q9HC97 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006932 0.94 SMN1; SMN2 (0.46) THRBL3MBTL1SMN1; SMN2ALDH1A1MEN1
SCHEMBL3008158 0.94 SMN1; SMN2 (0.46) THRBL3MBTL1SMN1; SMN2ALDH1A1MEN1
SCHEMBL3023020 0.94 THRB (0.48) THRBL3MBTL1SMN1; SMN2ALDH1A1MAPK1
SCHEMBL3022681 0.94 THRB (0.46) THRBL3MBTL1SMN1; SMN2ALDH1A1MEN1
SCHEMBL3002305 0.93 SMN1; SMN2 (0.47) THRBL3MBTL1SMN1; SMN2ALDH1A1MEN1
SCHEMBL3009001 0.92 SMN1; SMN2 (0.46) THRBL3MBTL1SMN1; SMN2ALDH1A1MEN1
SCHEMBL3020518 0.92 THRB (0.45) THRBL3MBTL1SMN1; SMN2ALDH1A1MEN1
SCHEMBL3011691 0.92 THRB (0.49) THRBL3MBTL1SMN1; SMN2ALDH1A1MEN1
SCHEMBL3014321 0.92 THRB (0.57) THRBL3MBTL1SMN1; SMN2ALDH1A1MEN1
SCHEMBL3008811 0.92 THRB (0.47) THRBL3MBTL1SMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA THRB 2628/4885L3MBTL1 1847/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.